BNS enters the back half of July with bears firmly in retreat — short interest has collapsed by more than a quarter over the past month while the stock climbs to levels last seen years ago.
The lending market tells the clearest version of this story. Borrow availability has exploded to 2,656% — meaning there are more than 26 shares available to lend for every one currently borrowed — the loosest conditions seen in at least a year. That is up sharply from around 995% just eight sessions ago on July 7, when the market briefly tightened. Cost to borrow spiked to nearly 10% on that same day, an obvious outlier against the surrounding days of sub-2% rates. By July 14, it had collapsed back to 0.57%. The spike and rapid retreat suggest a brief, tactical demand for borrows — not a structural rebuild of short conviction. Short interest itself has dropped 27% over the past month to just 1.46% of the free float, a level that carries no meaningful squeeze risk in either direction.
The ORTEX short score underscores how dramatically the bear case has faded. It read 42.8 on July 7 — the same session that saw the CTB spike — and has since fallen to 32.5, close to the lowest point in the recent 10-day window. That rapid decompression in the short score, aligned with the borrow normalisation and SI decline, points to shorts unwinding rather than fresh positioning building.
The stock's own performance has done most of the talking. BNS closed Tuesday at CAD 125.25, up 2.4% on the week and nearly 6.7% over the past month. The week's move puts BNS well ahead of its closest peers: TD managed just 0.3% on the week, BMO 0.5%, and RY 1.4%. CM added 1.2%. BNS's outperformance stands out across the Canadian bank cohort, though the group broadly drifted higher alongside a constructive tone in global financials. The price-to-book ratio has expanded to 1.87x, up from roughly 1.67x a month ago — a meaningful re-rating for a stock that until recently was valued at a discount to peers. The P/E sits at 14.1x, also up roughly a full turn over 30 days.
The analyst picture is thin. The consensus carries a buy, but coverage is narrow — two buy-rated analysts against one underperform — and no rating changes have been filed recently. The mean price target on record is CAD 117.21, which sits below the current price of 125.25; given the absence of recent updates, that figure is best treated as stale rather than as an anchor. The dividend score ranks in the 84th percentile, the standout factor on the scorecard. EPS momentum over 90 days is a reasonable 64th percentile, though the 30-day reading has slipped to 43rd and the forward earnings growth rank is a weak 27th — suggesting the re-rating has been driven more by sentiment and rate expectations than by fundamental upgrade momentum.
Institutional ownership is broadly stable. BMO Asset Management remains the largest reported holder with roughly 4.5% of shares. There is no fresh insider activity worth flagging — the most recent trades on record are December 2025 sells at prices well below current levels, offering little signal for today's setup.
With Q2 results due August 25, the attention will shift to whether BNS can justify its expanded valuation with evidence that Latin American revenue exposure is holding up and domestic loan loss provisions are not accelerating — the two variables that most distinguish its earnings profile from the rest of the Canadian bank group.
See the live data behind this article on ORTEX.
Open BNS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
